| All Patients N = 10,863 | Denosumab n = 1,235 | Alendronate n = 5,458 | Ibandronate n = 1,696 | Risedronate n = 1,341 | Raloxifene n = 805 | Teriparatide n = 328 | P Valuea | |
|---|---|---|---|---|---|---|---|---|
| CCI, mean (SD) | 0.8 (1.2) | 0.8 (1.3) | 0.8 (1.2) | 0.8 (1.2) | 0.8 (1.2) | 0.8 (1.3) | 0.8 (1.2) | 0.4451 |
| Number of ICD-9-CM diagnoses,b mean (SD) | 13.4 (8.5) | 13.2 (8.4) | 13.5 (8.6) | 13.3 (8.3) | 13.4 (8.2) | 13.3 (7.9) | 13.3 (9.4) | 0.9185 |
| Number of unique NDCs,c mean (SD) | 16.4 (12.8) | 16.7 (13.2) | 16.4 (12.7) | 16.1 (12.7) | 16.3 (12.9) | 16.8 (13.0) | 16.2 (13.8) | 0.8078 |
| Diagnosis of osteoporosis, n (%) | 3,947 (36.3) | 441 (35.7) | 1,992 (36.5) | 605 (35.7) | 488 (36.4) | 297 (36.9) | 124 (37.8) | 0.9637 |
| Diagnosis of osteopenia, n (%) | 1,264 (11.6) | 162 (13.1) | 629 (11.5) | 198 (11.7) | 155 (11.6) | 89 (11.1) | 31 (9.5) | 0.4873 |
| Osteoporosis therapy, n (%) | 3,263 (30.0) | 376 (30.4) | 1,640 (30.0) | 497 (29.3) | 397 (29.6) | 254 (31.6) | 99 (30.3) | 0.9072 |
| Osteoporosis-related fractures, n (%) | 1,512 (13.9) | 166 (13.5) | 772 (14.2) | 233 (13.7) | 175 (13.1) | 122 (15.1) | 44 (13.4) | 0.7971 |
| Renal insufficiency, n (%) | 446 (4.1) | 51 (4.1) | 215 (3.9) | 70 (4.1) | 59 (4.4) | 39 (4.8) | 12 (3.6) | 0.8681 |
| GI disorders, n (%) | 4,178 (38.5) | 478 (38.7) | 2,100 (38.5) | 633 (37.3) | 526 (39.3) | 321 (39.9) | 120 (36.7) | 0.7861 |
aP values calculated using χ2 tests for categorical variables and analysis of variance for continuous variables across therapies.
bNumber of unique ICD-9-CM diagnosis codes at the 3-digit level on medical claims.
cNumber of unique NDC numbers at the generic level from outpatient pharmacy claims.
CCI = Charlson Comorbidity Index; GI = gastrointestinal; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; NDC = National Drug Code; SD = standard deviation.